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Abstract
Purpose The goal of this study is to assess how reliable the
threshold maximum standardized uptake value (maxSUV) of
2.5 on positron emission tomography–computed tomogra-
phy (PET/CT) is for evaluation of solitary pulmonary lesions
in an area of endemic granulomatous disease and to consider
other imaging findings that may increase the accuracy of
PET/CT.
Materials and methods The staging PET/CT of 72 sub-
jects with solitary pulmonary lesions (nodules (less than
3 cm) or masses (greater than 3 cm)) were retrospectively
reviewed. Pathology proven diagnosis from tissue samples
was used as the gold standard. Logistic regression was used
to assess whether the subject’s age, maxSUV, size of
lesion, presence of emphysema, or evidence of granulom-
atous disease was predictive of malignancy.
Results Malignant lesions were identified in 84.7 %
(61/72) of the 72 subjects. A threshold maxSUV of 2.5 had
a sensitivity of 95.1 % (58/61), specificity of 45.5 %
(5/11), positive predictive value of 90.6 % (58/64), nega-
tive predictive value of 62.5 % (5/8) and an accuracy of
87.5 % (63/72). The false negative rate was 4.9 %, and the
false positive rate was 54.5 %. All 3 false negatives were
less than or equal to 1.0 cm; however, false positives
ranged from 1.1 to 5.6 cm. The false negatives had a
mean (SD) maxSUV of 2.0 (0.4), whereas the false posi-
tives had a mean (SD) maxSUV of 5.6 (3.0). Emphysema
was associated with 1.1 higher odds of malignancy, and
evidence of granulomatous disease was associated with
0.34 lower odds of benign disease, however, neither was
statistically significant (p = 0.92 and p = 0.31, respec-
tively). Higher maxSUV was significantly associated with
increased risk of malignancy (p = 8.3 9 10-3). Older age
and larger size of lesion were borderline associated with
increased risk of malignancy (p = 0.05 and p = 0.07,
respectively).
Conclusion In an area of high endemic granulomatous
disease, the PET/CT threshold maxSUV of 2.5 retains a
high sensitivity (95.1 %) and positive predictive value
(90.6 %) for differentiating benign from malignant pul-
monary lesions; however, the specificity (45.5) and nega-
tive predictive value (62.5) decrease due to increased false
positives. The presence of emphysema and absence of
evidence of granulomatous disease increases the probabil-
ity that a pulmonary lesion is malignant; however, these
were not statistically significant.
Keywords PET/CT  Solitary pulmonary nodule 
Granulomatous disease  Emphysema
Introduction
18-Fluorodeoxyglucose (FDG) positron emission tomo-
graphy–computed tomography (PET/CT) is an imaging
modality that is often used to help differentiate benign from
malignant pulmonary lesions [1]. PET/CT has also been
shown to improve the accuracy of staging non-small cell
lung cancer [2]. The fusion modality PET/CT has gained
popularity because of its higher accuracy for evaluation of
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lesions compared to either PET or CT alone [3, 4].
Malignant lesions have been shown to have elevated
expression of the glucose transporter (GLUT-1) and tend to
have increased metabolic activity evidenced by increased
FDG uptake [5]. However, several benign conditions have
also been noted to have increased metabolic activity
including infections, granulomatous disease and tubercu-
losis [6–8]. The threshold maximum standardized uptake
value (maxSUV) of 2.5 has been suggested as having
reasonable receiver operator characteristics to differentiate
benign from malignant pulmonary lesions [9].
We investigate the performance of PET/CT in subjects
from Northern California where there is highly endemic
granulomatous disease (coccidioidomycosis) [10]. Unlike
several prior series investigating the use of PET/CT, all
diagnoses were confirmed by histopathology. The accu-
racy, sensitivity and specificity of the threshold maxSUV
value of 2.5 for evaluation of lesions were calculated.
Finally we considered other imaging features that may
increase the reader accuracy of PET/CT.
Materials and methods
Subjects
The study was approved by the Institutional Review Board
(IRB) at the University of California, San Francisco
Medical Center.
The data are derived from retrospective review of the
medical records and imaging of 72 subjects who underwent
either fine needle aspiration (FNA) or surgical biopsy of
solid solitary pulmonary lesions resulting in a definitive
pathologic diagnosis and had a PET/CT study performed
for evaluation of the solitary pulmonary lesion in the
2 months prior to the surgical biopsy or FNA. All PET/CT
studies were performed between January 2010 and
November 2011.
Imaging technique
All subjects underwent whole body non-contrast enhanced
PET/CT, and all scans were acquired using the same PET/
CT scanner [General Electric (GE) Discovery 690 (Wis-
consin, USA)]. A 64 slice General Electric LightSpeed
multi-detector VCT was the Computed Tomography (CT)
scanner used in the PET/CT system. The arms were posi-
tioned above the subject’s head for CT acquisition, except
for subjects with restricted range of movement or shoulder
pathology where subject’s arms were positioned at the
subject’s sides.
Subjects fasted for at least 6 h prior to the study. CT was
acquired from the vertex to the toes without intravenous
contrast approximately 60 min following the intravenous
administration of 9.0–12.0 mCi (3.33 9 102 to 4.44 9 102
MBq) of FDG, followed by an emission positron emission
tomography (PET) scan. PET images were attenuation
corrected using the CT transmission data. Axial, coronal
and sagittal PET images with and without attenuation
correction, and a rotating three-dimensional (3D) maxi-
mum intensity projection (MIP) image, were obtained for
study interpretation. The non-attenuated corrected images
were reviewed because these images are sometimes more
accurate for evaluation of pulmonary nodules [11].
Acquired CT and fused PET/CT images were reviewed
alongside the uncorrected and corrected PET images. The
blood glucose level was less than 160 mg/dL at the time of
FDG injection for all subjects.
Image interpretation
All studies were evaluated by a physician certified in
Nuclear Medicine by the American Board of Nuclear
Medicine (ABNM). The size (maximum dimension) and
maximum standardized uptake value (maxSUV) of each
pulmonary nodule was recorded. Evidence of prior granu-
lomatous disease (calcified hilar or mediastinal lymph
nodes, calcified pulmonary nodules, liver or splenic gran-
ulomas) and presence of emphysema were noted.
Statistics
Statistics were performed using Rv2.9.1 statistical software
(www.r-project.org). Exact two-sample tests of proportion
were used for comparison of two proportions.
Results
The mean (range) age in the cohort was 69.9 (54–91) years.
A total of 72 lesions were identified with a diagnosis based
on histopathology. The mean (range) lesion size was 3.0
(0.8–11.0) cm. The mean (range) maxSUV was 10.8
(0.8–36.8). 70.8 % (51/72) of subjects had emphysema and
25.0 % (18/72) had evidence of granulomatous disease
(Table 1).
Most (84.7 %) of the lesions with histopathological
diagnoses were malignant, and most (96.7 %) of these
lesions were primary bronchogenic malignancies. The
most common malignancies were adenocarcinoma [47.5 %
(29/61)], squamous cell carcinoma [32.8 % (20/61)],
unspecified non-small cell lung cancer [11.5 % (7/61)] and
metastases [3.3 % (2/61)]. Not all of the lesions that were
biopsied were malignant. 15.3 % (11/72) of the biopsied
lesions were benign. The most common benign lesions that
were biopsied were inflammatory lesions [8.3 % (6/72)],
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granulomatous lesions (tuberculosis and coccidiodomyco-
sis) [4.2 % (3/72)], non-granulomatous infection [1.4 %
(1/72)] and nodular pulmonary amyloidosis [1.4 % (1/72)]
(Table 2).
Using a maxSUV threshold of 2.5, 63/72 biopsied
lesions were characterized correctly according to biopsy
results giving an accuracy of 87.5 %. The sensitivity and
specificity using the maxSUV threshold of 2.5 was 95.1 %
(58/61) and 45.5 % (5/11), respectively (Table 3). The
three false negative lesions (3/72) had a mean (SD) max-
SUV of 2.1 (0.4) and a mean (SD) size of 8.7 (1.2) mm.
The false positive lesions (6/72) had a mean (SD) maxSUV
of 5.6 (3.0) and a mean (SD) size of 24 (17.2) mm.
Older individuals were more likely to have malignant
lesions, however, this was borderline statistically signifi-
cant (p = 0.05). Larger lesions were more likely to be
malignant, however, this was also borderline statistically
significant (p = 0.07). Higher metabolic activity measured
by maxSUV was significantly associated with increased
risk of malignancy (p = 8.3 9 10-3) (Table 4). In the
multivariate analysis, the presence of emphysema was
associated with an increased risk of malignancy, however,
this was not statistically significant (p = 0.92). The power
of this analysis was limited because most subjects had
emphysema. Similarly, evidence of prior granulomatous
disease was associated with a decreased risk of malig-
nancy, however, this was not statistically significant
(p = 0.31).
Figure 1 shows a plot of the maxSUV versus size of
pulmonary lesion. There was a positive correlation
between the size of the lesion and the maxSUV (r = 0.71,
p = 6.2 9 10-7) indicating that larger lesions were asso-
ciated with increased metabolic activity and therefore
increased risk of malignancy, however, some of the larger
lesions were also benign.
Discussion
PET/CT remains a useful tool for the evaluation of solid
solitary pulmonary lesions. It has been postulated that a
solid pulmonary nodule with a maxSUV greater than 2.5 in
the right clinical setting should be considered suspicious
for malignancy. However, with this maxSUV threshold of
2.5, there are both false positives and false negatives. In
our study, we noted far more false positive than false
negative results. The increased false positive results were
in part related to endemic granulomatous disease. The false
negative results were likely related to the small size of the
lesion (less than 10 mm). Only one of the six lesions that
were less than 10 mm had a maxSUV greater than 2.5. The
false positive results were due to infections, including
tuberculosis and coccidiodomycosis. These false positive
lesions were on average 9.6 mm smaller, but this was not
statistically significant (p = 0.25), however, the false
positive lesions did have significantly lower maxSUV
values than the true positive lesions (p = 8.0 9 10-4).
Figure 2 shows a subject with a false positive PET/CT due
to a hypermetabolic coccidiodoma.
The accuracy, sensitivity, specificity, negative predic-
tive value and positive predictive value of the maximum
SUV threshold of 2.5 in this study were 87.5, 95.1, 45.5,
62.5, and 90.6 %, respectively. The sensitivity and speci-
ficity of a test are fixed parameters, which do not change,
however, the positive and negative predictive values of a
test varies depending on the underlying disease prevalence.
The subjects in our study were from Northern California,
an area that has a high prevalence of granulomatous dis-
ease, which contributed to some of the false positive
findings.
Our results are similar to previously published studies.
First, we find that bronchogenic carcinoma was the most
frequent cause of hypermetabolic solid pulmonary lesions,
similar to Ost et al. [8]. The lesion size, age, smoking
history and nodule margins are known risk factors for
Table 1 Study sample characteristics
Mean (SD) Range
Age 69.9 (9.0) 54–91
Sex (Male %) 97.2 % (70/72) –
Size (mm) 30.3 (22.0) 8–110
Maximum SUV 10.8 (7.8) 0.8–36.8
Presence of emphysema % (proportion) 70.8 % (51/72) –
Evidence of granulomatous disease %
(proportion)
25.0 % (18/72) –










Squamous cell 27.8 (20/72)
Unspecified NSCLC 9.7 (7/72)
Metastases 2.7 (2/72)
Small cell lung cancer 1.4 (1)
Large cell neuroendocrine carcinoma 1.4 (1)
Sarcomatoid carcinoma 1.4 (1)
402 Ann Nucl Med (2013) 27:400–405
123
malignancy [8, 12, 13]. In our study, we also find that age
(older individuals), and size of lesion (larger lesions) were
borderline significant risk factors for nodules being
malignant. We also found some evidence that smoking
history evidenced by the presence of emphysema was
associated with an increased risk of malignancy, however,
this was not statistically significant. Li et al. [14] have
found that there are increased false positive PET findings in
areas with a high prevalence of tuberculosis (TB). Our
results also show that there are also increased false positive
PET/CT findings in areas with a high prevalence of ende-
mic granulomatous disease.
PET/CT has decreased accuracy in evaluating small
pulmonary nodules due to partial volume effect, in par-
ticular nodules less than 8 mm [15], and is therefore only
recommended by the Fleischner Society for evaluation of
pulmonary nodules greater than 8 mm in size or in patients
with a history of malignancy [16]. In our study, the false
negative results occurred with lesions that were less than
10 mm in size.
This study was done evaluating single time point PET/
CTs. Dual time point PET/CT has been proposed as
another method of evaluating solitary pulmonary nodules
with conflicting evidence. In one study, dual time point
PET/CT appeared to be valuable in differentiating benign
Table 3 PET/CT maximum SUV threshold of 2.5 performance for characterization of solitary pulmonary nodules
Accuracy (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
All (N = 72) 87.5 (63/72) 95.1 (58/61) 45.5 (5/11) 90.6 (58/64) 62.5 (5/8)
Emphysema (N = 51) 84.3 (43/51) 92.9 (39/42) 44.4 (4/9) 88.6 (39/44) 57.1 (4/7)
Granulomatous disease (N = 18) 83.3 (15/18) 92.9 (13/14) 50.0 (2/4) 86.7 (13/15) 66.7 (2/3)
Emphysema without granulomatous disease (N = 42) 88.1 (37/42) 94.4 (34/36) 50.0 (3/6) 91.9 (34/37) 60.0 (3/5)
Granulomatous disease without emphysema (N = 9) 100 (9/9) 100 (8/8) 100 (1/1) 100 (8/8) 100 (1/1)
PPV positive predictive value
NPV negative predictive value
Emphysema—all subjects with emphysema
Emphysema without granulomatous disease—subjects with only emphysema
Granulomatous disease—all subjects with granulomatous disease
Granulomatous disease without emphysema—subjects with only granulomatous disease
Table 4 Logistic regression evaluating predictors of malignancy
Variable Odds
ratio
95 % CI p value
Univariate
Age 1.10 (1.00,1.20) 0.05*
Size of lesion (mm) 1.05 (1.00, 1.11) 0.07
MaxSUV 1.47 (1.10, 1.96) 8.3 9 10-3*
Presence of emphysema 0.52 (0.10, 2.65) 0.43
Evidence of granulomatous
disease
0.52 (0.13, 2.05) 0.35
Multivariatea
Presence of emphysema 1.11 (0.13, 9.19) 0.92
Evidence of granulomatous
disease
0.34 (0.04, 2.67) 0.31
* p value B0.05
a Multivariate analyses adjusted for age, size of lesion and maximum
SUV
Fig. 1 Plot of Maximum SUV
versus lesion size
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from malignant solitary pulmonary nodules in areas of
high prevalence of granulomatous disease [7]. However,
other studies have shown that dual time point PET/CT has
similar accuracy compared to single time point PET/CT
[17, 18], and Chen et al. [6] conclude that dual time point
PET/CT was not useful, especially in areas with a high
prevalence of granulomatous disease [6]. These discrepant
results may be due to differences in technique. The
maximum FDG uptake for lung cancers occurs at around
5 h (300 min) after injection, and therefore dual time
point PET/CT imaging may in some cases appear no
better than single time point PET/CT imaging if the
second imaging is done 120–180 min after injection of
the radiotracer [19].
There are a few limitations to our study. First, the study
was retrospective in nature and therefore subject to case
selection bias. Another limitation of our study was that the
lesions that did not go on to excision/biopsy were excluded
from the analysis. Although this is a limitation, it is also a
strength of this study. Histopathologic proof was used to
determine the diagnosis of each of the pulmonary lesions.
This diminishes uncertainty and potential misdiagnoses
that can occur when criteria such as lack of interval change
on imaging studies are used for indicating the true diag-
noses of the pulmonary lesions. Most of the subjects in the
study were male, which may limit generalizability of the
results. Finally, we use the common maximum SUV
threshold value of 2.5, which has been challenged in the
literature as being too high and not specific enough to rule
in underlying malignancy [20, 21]. While there remains
significant debate around this threshold, at our institution,
all lesions that are not excised/biopsied are followed for at
least 2 years to document stability.
Evaluation of solitary pulmonary nodules remains a
diagnostic challenge. Over 150,000 patients annually present
to their physicians with the diagnostic dilemma of a solitary
pulmonary nodule found either on chest X-ray or chest CT
[22]. Lung cancer has the highest incidence and highest
mortality in the United States [23], and early detection of
lung cancers greatly improves survival [23]. This study
substantiates the use of PET/CT for characterization of solid
pulmonary lesions in subjects from areas with endemic
granulomatous disease; however, there are increased false
positive findings due to granulomatous disease in this setting.
Summary
In an area of high endemic granulomatous disease, the
PET/CT threshold maxSUV of 2.5 retains a high sensitivity
(95.1 %) and positive predictive value (90.6 %) for dif-
ferentiating benign from malignant pulmonary lesions;
however, the specificity (45.5 %) and negative predictive
value (62.5 %) decrease due to increased false positives.
This suggests that further work needs to be done to assess
how the performance of PET/CT can be improved to
evaluate solid solitary pulmonary lesions in patients from
areas with endemic granulomatous disease. The presence
of emphysema and absence of evidence of granulomatous
disease increases the probability that a pulmonary nodule is
malignant; however, these were not statistically significant
(p = 0.92 and p = 0.31, respectively).
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Fig. 2 Fused PET/CT image (left) and non-attenuated corrected PET image (right) demonstrating an intense FDG uptake in a coccidiodoma
seen in the left lung
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